|
End-of-day quote
Shanghai S.E.
2026-08-18
|
5-day change | 1st Jan Change | ||
| 3.930 CNY | 0.00% |
|
+3.97% | -1.26% |
| Market Cap | 3.08B 457M 395M 371M 338M 635M 43.8B 644M 4.36B 1.71B 21.91B 1.72B 1.68B 72.96B | P/E 2024 |
-8.86x | P/E 2025 | -9.48x |
|---|---|---|---|---|---|
| Enterprise Value | 3.3B 489M 423M 398M 361M 680M 46.88B 690M 4.66B 1.83B 23.45B 1.84B 1.8B 78.1B | EV / Sales 2024 |
1.48x | EV / Sales 2025 | 1.79x |
| Free-Float |
68.56% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | +3.97% | ||
| Current month | +10.39% | ||
| 1 month | +15.93% | ||
| 3 months | +0.26% | ||
| 6 months | -2.00% | ||
| Current year | -1.26% |
| 1 week | 3.7 |  | 4.05 |
| 1 month | 3.15 | | 4.1 |
| Current year | 2.85 | | 5.27 |
| 1 year | 2.85 | | 5.27 |
| 3 years | 2.76 | | 6.15 |
| 5 years | 2.76 | | 8.8 |
| 10 years | 2.76 | | 20.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ya Qi Dou
CEO | Chief Executive Officer | 42 | 2021-05-12 |
Xianti Zeng
DFI | Director of Finance/CFO | 52 | 2024-09-05 |
Zhi Wei Wang
PRN | Corporate Officer/Principal | 56 | 2019-09-16 |
| Director | Title | Age | Since |
|---|---|---|---|
Qi Ling Dou
CHM | Chairman | 66 | 2009-01-21 |
Zhi Wei Wang
BRD | Director/Board Member | 56 | 2011-02-20 |
Ya Qi Dou
BRD | Director/Board Member | 42 | 2019-01-02 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +3.97% | -5.98% | -28.15% | 457M | |
| +3.07% | +0.15% | +74.32% | +122.69% | 1,055B | |
| +3.46% | +4.26% | +53.68% | +57.03% | 632B | |
| +3.22% | +3.06% | +24.77% | +71.67% | 442B | |
| +1.35% | -2.17% | +40.98% | +41.50% | 351B | |
| +1.75% | -0.24% | +25.28% | +40.46% | 290B | |
| +2.13% | -0.32% | +0.58% | +10.77% | 243B | |
| +1.50% | +2.75% | +45.48% | +62.59% | 227B | |
| +1.35% | -3.53% | -14.72% | -52.63% | 200B | |
| +3.50% | +5.64% | +21.56% | +89.02% | 172B | |
| Average | +2.18% | -1.17% | +26.60% | +41.50% | 361.3B | |
| Weighted average by Cap. | +2.68% | -1.87% | +43.23% | +67.82% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.17B 322M 278M 262M 238M 448M 30.89B 454M 3.07B 1.2B 15.45B 1.21B 1.18B 51.46B | 1.86B 276M 239M 224M 204M 384M 26.47B 389M 2.63B 1.03B 13.24B 1.04B 1.01B 44.09B |
| Net income | -317M -47.04M -40.63M -38.23M -34.74M -65.34M -4.51B -66.3M -448M -176M -2.25B -177M -173M -7.51B | -330M -48.87M -42.21M -39.71M -36.09M -67.89M -4.68B -68.88M -466M -183M -2.34B -183M -180M -7.8B |
| Net Debt | 411M 60.93M 52.62M 49.51M 45M 84.64M 5.84B 85.88M 581M 228M 2.92B 229M 224M 9.73B | 217M 32.2M 27.81M 26.16M 23.78M 44.72M 3.08B 45.38M 307M 120M 1.54B 121M 118M 5.14B |
Employees
4,832
Sector
Pharmaceuticals
Calendar
Aug. 21
Earnings release - Q2 2026
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-17 | CN¥3.930 | 0.00% | 42,336,500 |
| 26-08-17 | CN¥3.930 | +1.29% | 36,016,200 |
| 26-08-14 | CN¥3.880 | -1.02% | 31,661,635 |
| 26-08-13 | CN¥3.920 | +1.03% | 53,938,879 |
| 26-08-12 | CN¥3.880 | +1.31% | 41,702,400 |
- Stock Market
- Stocks
- 600594 Stock
Select your edition
All financial news and data tailored to specific country editions
